Jakavi

Ruxolitinib Phosphate

Method of action: Antitumour

Treatment option: Myelofibrosis, Primary Myelofibrosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Jakavi

Property	Description
Active Ingredient	Ruxolitinib Phosphate
Form	Oral tablet (Systemic delivery)
Pharmacological Class	Janus Kinase (JAK) Inhibitor
General Purpose	Management of conditions driven by excessive cellular activity and chronic inflammation
Origin	Synthetic, Small Molecule

What Type of Medicine is Jakavi (Ruxolitinib)?

Jakavi is a prescription-only, synthetic small molecule drug whose unique identity lies in its pharmacological classification as a Janus Kinase (JAK) inhibitor. This positions it as a targeted therapy, a therapeutic approach that is clinically recognized for precisely modulating the specific mechanisms of disease, as opposed to broader systemic suppression. The drug is classified as an antineoplastic agent and an immunomodulating agent, confirming its utility in managing conditions rooted in dysregulated cell growth and immune responses.

Ruxolitinib Composition and Delivery Form

The active ingredient in Jakavi is Ruxolitinib, which is formulated and delivered as the salt Ruxolitinib Phosphate. As a single-agent product, its therapeutic efficacy depends solely on the Ruxolitinib component. For achieving systemic delivery throughout the body, Jakavi is most commonly supplied as an oral tablet for administration by mouth. This oral form is crucial for patients requiring continuous, long-term therapeutic management, offering the convenience of an orally bioavailable therapy.

How Does Jakavi Generally Help the Body?

The general purpose of the medicine is to help manage conditions characterized by dysregulated cell proliferation and chronic inflammation by selectively blocking specific intracellular signals. Ruxolitinib acts as a highly selective blocker against the key enzymes JAK1 and JAK2, which are often overactive in disease states and transmit signals from inflammatory proteins. By interfering with the function of these Janus Kinases, the drug effectively slows the transmission of underlying signals that promote abnormal cellular activity, thereby helping to moderate the overall disease process. This action provides a targeted approach to controlling the underlying mechanism of these conditions.

Regulatory References

NIH MedlinePlus Ruxolitinib

What side effects are possible with Jakavi?

Possible Side Effects and Safety Information

The safety profile of Jakavi (ruxolitinib) is primarily characterized by effects on blood counts, infections, and certain organ system disorders. All information is based on authoritative government regulatory labeling, such as that provided by the FDA and EMA.

Adverse Reactions by Frequency and System

The most commonly reported adverse reactions are Very Common (occurring in more than 1 in 10 patients) and involve the blood system and general symptoms:

Hematologic: Thrombocytopenia (low platelet count), Anemia (low red blood cell count), and Neutropenia (low white blood cell count) are frequent and may require dose adjustments or interruption of treatment.
Other Very Common: Bruising/Bleeding, Dizziness, Headache, Weight Gain, Urinary Tract Infections, Hypercholesterolaemia (high cholesterol), and Hypertriglyceridaemia.

Serious Adverse Reactions and Key Warnings

Treatment is associated with risks of Serious Infections, including bacterial, fungal, viral (e.g., Herpes Zoster, Tuberculosis), and opportunistic infections like Progressive Multifocal Leukoencephalopathy (PML). Patients must be evaluated for active or latent infections before starting treatment.

Other serious risks include Non-Melanoma Skin Cancer (requiring regular skin checks), and a documented risk of thrombosis (blood clots in the legs or lungs). Abrupt interruption of the medicine may lead to an acute worsening of underlying disease symptoms (rebound phenomena).

Safety Restrictions and Monitoring

Dose-Related Patterns: Cytopenias are most frequent during the first few months of therapy. Dose reductions are officially mandated for patients with severe renal impairment or any degree of hepatic impairment. Dosing must be adjusted based on the patient's platelet and neutrophil counts. Women who are pregnant or breastfeeding should not take this medicine.

Overdose and Emergency Response

Overdose Scope

Property	Official Regulatory Statement/Entity
Documented overdose presentations	Manifestations may include an acute exaggeration of known effects, such as unusual bleeding or bruising, dizziness, headache, and signs of infection like fever and sore throat.
Physiological systems affected (as stated in label)	Primarily the hematological system (evidenced by expected thrombocytopenia, anemia, and neutropenia) and the nervous system (evidenced by dizziness, headache, seizure, and collapse).
Dose-related or exposure-related factors (if applicable)	Single exposures to doses up to 2000 mg have been documented, correlating with increased severity of undesirable effects, primarily hematological toxicity.
Population-specific overdose notes (if applicable)	No explicit, distinct overdose-specific considerations are documented in regulatory labeling for specific populations beyond routine dose adjustments for normal use.
Emergency-response statements (as written in official documents)	Contact the poison control helpline is directed. Immediately call emergency services (e.g., 911 or local equivalent) if severe symptoms occur.
When immediate medical help is required (label-derived phrasing only)	Urgent medical attention is required if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Aspect	Official Regulatory Statement/Entity
Severity classification (as defined in official documents)	The profile defines a spectrum from acute, manageable symptoms to life-threatening collapse events that mandate immediate emergency service contact.
Regulatory basis (EMA / FDA / etc.)	Information is derived from official regulatory labeling, including the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents)	Overdose management is limited to symptomatic and supportive treatment, as no specific antidote is known, and requires careful monitoring of blood cell counts.

Resulting Overdose Structure

Official overdose statements:

Overdose may present with an acute increase in the expected adverse reactions, including unusual bleeding or bruising and systemic signs of infection.
In the event of an overdose, immediate contact with a poison control helpline is directed.
Urgent medical attention is required for severe manifestations, explicitly including collapse, seizure, trouble breathing, or the person being unable to be awakened.
Management consists of providing symptomatic and supportive treatment and requires careful monitoring of hematological parameters.
No specific antidote is known for Ruxolitinib overdose.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the Ruxolitinib overdose profile by focusing on the acute exaggeration of its known hematological toxicities and systemic effects. The official instructions strictly delineate that urgent medical help is required when specific, life-threatening neurological and respiratory symptoms are present. Given the absence of a known specific antidote, the regulatory guidance for treatment mandates intensive supportive care and rigorous physiological monitoring.

Therapeutic Uses of Jakavi

The medication is relevant for managing conditions that include myelofibrosis (MF), polycythemia vera (PV), and graft-versus-host disease (GvHD).

Managing Systemic Symptom Burden

Jakavi is commonly used for managing the symptom burden associated with chronic blood disorders, such as MF and PV. It is applied across therapeutic domains where additional symptomatic support is needed for symptoms that interfere with daily functioning—including night sweats, fevers, severe itching, and fatigue. The medication may assist with reducing the size of the enlarged spleen (splenomegaly) in MF, which contributes to improved comfort and general well-being.

Treatment Contexts and Patient Benefit

This medication is considered relevant for adult patients with PV whose condition is marked by heightened physiological activity and persistent symptoms, often following an inadequate response to or intolerance of prior standard cytoreductive therapy. A primary supportive benefit is assisting in the management of hematocrit levels, which supports patients during episodes of heightened discomfort. Additionally, the medication is applied when GvHD has not responded adequately to initial corticosteroid management in both adult and pediatric patients. This approach supports symptom management: it provides supportive relief when symptoms become temporarily overwhelming and contributes to easing the overall symptom load.

“It is commonly used in conditions presenting with systemic or localized discomfort and is applied in clinical settings that involve acute or unstable symptom patterns.”

Quick Fact: Symptomatic Relief

Quick Fact: Symptomatic Relief – The medication is used to help address clusters of symptoms, including night sweats, fevers, itching (pruritus), and fatigue, that create noticeable physiological strain in patients with myelofibrosis.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Jakavi's eligibility is strictly defined by specific medical conditions, hematological status, and physiological function, as outlined in official regulatory documents.

Populations Allowed

Myelofibrosis (MF): Adult patients diagnosed with primary, post-Polycythemia Vera, or post-Essential Thrombocythemia myelofibrosis, provided their platelet and absolute neutrophil counts meet minimum levels.
Polycythemia Vera (PV): Adult patients who have been documented as resistant to or intolerant of hydroxyurea.
Graft-versus-Host Disease (GvHD): Adult and pediatric patients (age limits apply) who have an inadequate response to corticosteroids or other systemic therapies.

Populations Excluded or Restricted

Contraindication: The medicine must not be used by patients with a known hypersensitivity to the active substance, ruxolitinib, or any of its components.
Age-Related Rules: Use for MF and PV is restricted to adult patients. For GvHD, the eligible pediatric age varies by regulatory agency (e.g., ge 28 days for acute GvHD in one agency, ge 12 years in another).
Physiological Constraints: Patients with severe renal impairment or any degree of hepatic impairment require a reduction in the starting dose. Use must be interrupted if on-treatment platelet or absolute neutrophil counts drop below specific critical thresholds (e.g., platelet count <50 imes 10^9/L).
Pregnancy and Lactation: Women who are pregnant or breastfeeding must not take Jakavi; breastfeeding should be discontinued for a specified time after the last dose.

What should I know about interactions with other medicines?

Jakavi (ruxolitinib) is primarily metabolized by the liver enzymes Cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP2C9. Therefore, its use with other medicines that affect these enzymes can significantly alter the level of Jakavi in the body, which requires dose adjustments.

Interactions Requiring Dose Reduction

Concomitant use of Jakavi with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 (such as the antifungal medicine fluconazole) increases Jakavi exposure. In these cases, the Jakavi dose must be reduced by approximately 50%. For example, the maximum recommended dose of fluconazole is 200 mg daily when co-administered with Jakavi; higher doses should be avoided. Increased monitoring of blood counts is required when combining these medicines.

Interactions Requiring Close Monitoring

Medicines that are strong CYP3A4 inducers, such as rifampicin, can cause a decrease in Jakavi exposure. In these cases, the Jakavi dose may need to be carefully increased (titrated) based on close monitoring of the patient’s safety and treatment effectiveness. Patients should inform their healthcare provider about all medicines, over-the-counter products, and herbal supplements, including St. John’s Wort (a known CYP3A4 inducer), as these may also require a change in the Jakavi dose.

Mechanism of Action

Molecular Mechanism: Janus Kinase Inhibition

Jakavi's mechanism begins at the molecular level by acting as an inhibitor of the intracellular enzymes Janus Kinase 1 (JAK1) and Janus Kinase 2 (JAK2). By blocking the catalytic function of these specific kinases, the drug interferes with an initial step of a fundamental cell signaling pathway.

Intracellular Cascade and Signaling

The inhibition of JAK1 and JAK2 prevents the activation of the downstream STAT proteins, thus interrupting the JAK-STAT signaling cascade. This action prevents the subsequent gene expression of molecules responsible for both cell proliferation and the production of numerous pro-inflammatory mediators.

Physiological Modulation

The resulting effect on the body is a dual modulation of two major systems. Inhibition of the JAK-STAT cascade regulates hematopoiesis (blood cell formation) that is driven by JAK2 signals, and at the same time, decreases the magnitude of JAK1-mediated inflammatory signaling.

Dosage and Administration Information

How to Use Jakavi (Ruxolitinib)

Official Administration Guidelines

Jakavi is provided as film-coated tablets for oral administration.

Administration Scope	Official Instruction
Route & Form	Oral; tablets must be swallowed whole (do not crush, break, or chew).
Timing & Food	Take the medicine twice daily (BID) at approximately the same time each day; it may be taken with or without food.
Dosing Range	The dose typically ranges from 5 mg to 25 mg taken twice daily. The starting dose and subsequent adjustments are determined by the healthcare provider based on the patient's specific indication and platelet count.
Missed Dose	If a dose is missed, do not take an extra dose to make up for the one that was missed. The patient should take the next scheduled dose at the usual time.

Required Dose Modifications

Treatment requires continuous professional monitoring. The prescribed dose must be modified by the healthcare provider under several specific conditions:

Laboratory Parameters: The dose will be adjusted, interrupted, or potentially discontinued if specific laboratory values, such as platelet or neutrophil counts, fall below defined thresholds.
Organ Function: Dose reduction is required for patients with severe renal impairment or hepatic impairment (mild, moderate, or severe) to maintain appropriate drug levels.
Drug Interactions: Dose adjustments (typically a reduction) are necessary when the medicine is co-administered with strong CYP3A4 inhibitors.

Treatment is typically continuous and of indefinite duration, provided the patient continues to meet the criteria for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Jakavi

Evidence for Use in Myelofibrosis (MF)

Research for Myelofibrosis (MF) relies primarily on pivotal randomized controlled trials (RCTs) involving adult patients with higher-risk MF. These studies monitored outcomes such as changes in the size of the enlarged spleen (splenomegaly) and measurements of systemic symptoms like night sweats, fatigue, and itching. Studies reported that a higher percentage of patients who received the active agent attained the pre-defined targets for both spleen size reduction and symptom score change compared to the control groups. Analyses describing overall survival described a difference in survival patterns between the randomized groups, even considering that control patients later started receiving the active treatment.

Evidence for Use in Polycythemia Vera (PV)

Research for Polycythemia Vera (PV) focused on adult patients whose condition was not adequately controlled by prior standard therapy. Phase 3 randomized trials examined a composite outcome, monitoring both a patient’s ability to achieve hematocrit control and a specified spleen volume reduction. Comparative trial data described that this composite endpoint was reported in a higher percentage of patients in the active treatment group. However, the current evidence is focused exclusively on the subgroup of patients who were resistant to or intolerant of hydroxyurea, concluding that the findings primarily describe patterns in patients who had already failed other therapies.

Evidence for Use in Graft-Versus-Host Disease (GvHD)

Jakavi was evaluated in comparative Phase 3 randomized trials for both acute (aGvHD) and chronic (cGvHD) GvHD in patients dependent on or refractory to corticosteroids. For acute GvHD, studies focused on the Overall Response Rate (ORR), reporting that the target ORR was measured in a greater percentage of patients in the active treatment group compared to the control group. Data related to the time until treatment failure or death (Failure-Free Survival) suggested a difference between the randomized groups. For chronic GvHD, studies also reported that the main outcome, ORR at Week 24, was measured in a higher proportion of patients in the active treatment group.

Key Studies & References

Ruxolitinib versus best available therapy for the treatment of chronic myelofibrosis: a randomized, open-label, phase 3 study (COMFORT-II)

Frequently Asked Questions (FAQ)

Common questions about Jakavi (FAQ)

Q: Will I have to take Jakavi for the rest of my life?

Jakavi treatment is typically continuous and of indefinite duration, provided the patient continues to meet official criteria for use and demonstrate benefit. Clinical protocols established in the product information may lead to discontinuation if there is no evidence of a response, such as spleen size reduction or significant symptom improvement, after 6 months of therapy for Myelofibrosis.

Q: Does Jakavi work right away, or does it take time to see effects?

Jakavi generally takes time to show its therapeutic effects. The initial period of treatment is managed according to specific protocols, with dose adjustments generally not occurring during the first 4 weeks. A patient's response, such as spleen size reduction and symptom control, is officially evaluated over several months, with treatment discontinuation considered if no improvement is seen after 6 months.

Q: What are the long-term side effects associated with Jakavi use?

Official information indicates the drug is associated with certain long-term risks, including Non-Melanoma Skin Cancer (for which skin monitoring is advised) and a risk of thrombosis (blood clots). Additionally, the class of medicines Jakavi belongs to has been associated with a possible increased risk of secondary cancers and major cardiovascular events in certain patient populations.

Q: How quickly can Jakavi help reduce spleen size?

The time it takes for Jakavi to reduce spleen size varies among patients. Clinical trial protocols typically establish a period of 6 months as the benchmark for determining an adequate therapeutic response. The lack of a specified reduction in spleen volume by this evaluation point may lead to a medical consideration of treatment discontinuation.

Q: Does my diet need to change significantly while I'm taking Jakavi?

Official regulatory documents state that Jakavi can be taken with or without food, so no significant dietary changes are required for administration. However, regulatory warnings specifically highlight that herbal supplements, such as St. John’s Wort, can affect how the body processes the medicine, and dose adjustments may be required by a healthcare provider.

Q: Does Jakavi cause fatigue or tiredness?

Fatigue, or unusual tiredness, is commonly related to anemia (low red blood cell count), which is listed in official documents as a Very Common adverse reaction of Jakavi. Prescribing information notes that patients should be monitored for signs and symptoms related to anemia.

Q: Is it normal to have some bruising while taking Jakavi?

Yes, bruising or bleeding is listed in the official safety information as a Very Common side effect, meaning it occurred in more than 1 in 10 patients in clinical trials. This is due to the drug's effect on platelet counts (thrombocytopenia), which can increase the risk of bleeding.

Q: How effective is Jakavi in reducing the need for blood transfusions?

Clinical trial data observed that changes in red blood cell transfusion dependency were approximately similar between the Jakavi and control groups, suggesting the drug may not improve anemia or transfusion dependence for all patients. Anemia itself is listed as a Very Common side effect of the medicine.

Q: Can Jakavi affect fertility in men or women?

Nonclinical (animal) studies found no effects on fertility in male or female animals. However, the studies did show evidence of harm to the developing fetus. For this reason, women who are pregnant or breastfeeding are advised in the product information not to take this medicine.

Q: Are there any documented drug-drug interactions with common antidepressants and Jakavi?

Jakavi is processed primarily by the liver enzyme CYP3A4. Official warnings focus on interactions with strong inhibitors and inducers of this enzyme. While specific antidepressants are not always named, some are known to affect CYP3A4 and may therefore require a dose adjustment by a healthcare provider.

Q: What happens if I stop taking Jakavi suddenly?

Abrupt interruption of Jakavi may lead to the return and acute worsening of underlying disease symptoms. This is known as a symptom exacerbation or rebound phenomena, and regulatory information advises that patients should not stop treatment without medical supervision.

Q: How long does it take for Jakavi to be eliminated from the body?

The pharmacokinetics data indicates that Jakavi is rapidly absorbed and largely processed by the liver. The elimination half-life (the time it takes for half the drug to be eliminated from the body) of the active ingredient is approximately 3 hours.

Q: How can I manage the skin-related side effects, like rashes, from Jakavi?

Official information advises patients of the risk of Non-Melanoma Skin Cancer and mandates that the skin should be examined periodically throughout treatment. Management strategies for common adverse reactions like rashes are not detailed in the official product information, but patients are generally advised to discuss all skin changes with their healthcare provider.

Q: Does Jakavi have any effect on blood clotting?

Yes, regulatory information indicates that Jakavi is associated with a risk of thrombosis (blood clots in the legs or lungs). Furthermore, it can cause thrombocytopenia (low platelet count), which is an important component of the blood clotting system.

Q: Is it normal to gain weight while taking Jakavi?

Yes, Weight Gain (or 'weight increased') is listed in official safety information as a Very Common adverse reaction. This means it was observed in more than 1 in 10 patients during clinical trials.

How should Jakavi be stored and disposed of?

Jakavi (ruxolitinib) tablets require storage under specific conditions defined by regulatory agencies to maintain product stability and quality.

Storage Requirements

Condition	Details
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Brief excursions are permitted up to 30 C (86 F).
Protection	Keep the tablets protected from moisture, heat, and direct light. Do not freeze the product.
Container	The medicine must be stored in the original, closed packaging.
Child Safety	It is mandatory to keep Jakavi out of the reach and sight of children.

Disposal Instructions

Outdated or unused medicine must be discarded according to local rules and the instructions of a healthcare professional. To protect the environment, the medicine must not be thrown away via wastewater or household waste and should be returned to a pharmacy or designated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.